# Inside the KLOW Peptide Stack: The Four Peptides — Blend Components

> Inside the KLOW stack — the four peptides dissected: KPV (10 mg), GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg). Mechanisms, CAS numbers, MW and the research behind each KLOW blend component.

KPV · GHK-Cu · BPC-157 · TB-500. Vial composition 50/10/10/10 mg. Mechanisms, MW and citations — one console card per arm.

## The short version

The KLOW stack is four research peptides co-dissolved in one vial. They are not one molecule — they are four separate chemicals that stay chemically independent after reconstitution. GHK-Cu makes up most of the vial by weight (50 of the 80 mg); the other three (BPC-157, TB-500, KPV) contribute 10 mg each. The stack has never been tested as a combination — every claim about what KLOW does as a unit is drawn from separate studies on each ingredient alone. This page lists what those studies found, channel by channel.

## KPV — anti-inflammatory channel (10 mg · CAS 67727-97-3 · MW 342.44 Da)

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH — a 13-amino-acid pituitary hormone involved in inflammation and pigmentation). Sequence: L-Lys-L-Pro-L-Val.

**Mechanism:** KPV suppresses NF-kB (nuclear factor kappa-B — the master transcription factor that drives inflammatory gene expression) and MAP-kinase signaling in epithelial and immune cells. At nanomolar concentrations it reduced TNF-alpha, IL-6 and IL-1beta in human intestinal cell lines and T cells [3]. It is a substrate of PepT1 (SLC15A1), the di/tripeptide transporter expressed on intestinal epithelial cells and upregulated in inflamed mucosa — giving KPV preferential gut-mucosal uptake at inflamed sites [3].

**Colitis evidence:** Oral KPV (100 micromolar in drinking water) reduced the severity of DSS- and TNBS-induced colitis in C57BL/6 mice, with lower myeloperoxidase activity and reduced inflammatory infiltrate [3][9]. A related tripeptide family analog (KdPT) preserved epithelial barrier function in experimental colitis [10].

**Colitis-associated cancer model:** KPV, delivered via PepT1, reduced inflammation-driven tumorigenesis in a murine colitis-associated cancer model [11].

**Human data:** Limited to delivery-pathway experiments and the IBD drug-program lineage; no approved human indication.

## GHK-Cu — matrix and copper channel (50 mg · CAS 89030-95-5 · MW 402.92 Da)

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) complex, also called Copper Tripeptide-1) is the mass-dominant arm. Sequence: Gly-His-Lys chelated 1:1 to a Cu(II) ion. First isolated from human plasma by Loren Pickart in 1973; plasma levels decline from about 200 ng/mL at age 20 to about 80 ng/mL by age 60 [4].

**Transcriptomic modulation:** At 1-10 nM, GHK modulated expression of approximately 31.2% of human protein-coding genes (at ≥50% change), increasing 59% of affected genes and suppressing 41%. Strongest signals: extracellular-matrix remodeling, antioxidant defense, DNA repair and ubiquitin-proteasome gene sets [5]. Note: the frequently cited '~4,000 genes' figure is an extrapolation; the ≥50% threshold data cover approximately 2,100 genes.

**Matrix synthesis:** Stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin. Supplies copper for lysyl oxidase (the copper-dependent enzyme that crosslinks collagen and elastin into stable fibers) [4].

**Skin clinical data:** Topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid in a reviewed clinical dataset [4]. Decades of topical cosmetic and wound-healing human use; no approved systemic indication.

**GHK behavioral data [12][13]:** Rodent studies found anxiolytic effects (GHK reduced anxiety-like behavior in behavioral testing [13]) and reduced pain-induced aggressive behavior [12] — early, context-specific results.

## BPC-157 — angiogenic repair channel (10 mg · CAS 137525-51-0 · MW 1419.53 Da)

BPC-157 (Body Protection Compound 157, also PL 14736) is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a protein sequence identified in human gastric juice. Developed by Sikiric et al. at the University of Zagreb.

**Core mechanism:** Activates the VEGFR2/PI3K/Akt/eNOS angiogenic axis (VEGFR2 = vascular endothelial growth factor receptor 2; the pathway that drives new blood-vessel formation), upregulates growth-hormone receptor in tendon fibroblasts, and modulates the nitric-oxide system in a manner partly resistant to L-NAME [2].

**Tendon repair [2]:** BPC 157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, histologic and macroscopic measures, and stimulated tendocyte outgrowth in vitro at doses of 10 microg, 10 ng and 10 pg per rat IP.

**Gut protection [8]:** In rat gastric-ulcer models, 400-800 ng/kg IM reduced ulcer formation at inhibition ratios of 45.7-65.6% and accelerated glandular-epithelium rebuilding.

**Recent BPC-157 data:**
- 2024 fistula model: accelerated duodenocolic fistula closure, consistent with cytoprotection [14].
- 2024 interstitial-cystitis pilot (n=12): complete symptom resolution in 10/12, all scored 5/5 on Global Response Assessment; no adverse events — but uncontrolled, not a trial [15].
- 2025 IV safety pilot: up to 20 mg IV in two healthy adults was well tolerated with no measurable changes in cardiac, hepatic, renal, thyroid or glucose markers [6].

**FDA status:** BPC-157 is NOT FDA-approved. It was placed in category 2 of the 503A bulk-substances review (meaning its inclusion in compounded preparations for human use requires further data for potential reclassification).

## TB-500 — cytoskeletal channel (10 mg · MW 889.02 Da)

TB-500 (Ac-LKKTETQ) is a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tbeta4). No CAS number is publicly registered for the fragment.

**Mechanism:** The LKKTET motif sequesters G-actin (monomeric globular actin — the building block of actin filaments). Sequestering G-actin shifts the cell's actin equilibrium in a way linked to increased cell migration and re-epithelialization. Native Tbeta4 also activates integrin-linked kinase and mobilizes epicardial progenitor cells — activities established for the full-length protein, not demonstrated for the TB-500 fragment [7].

**The foundational wound-healing result [1]:** In a rat full-thickness wound model, topical or intraperitoneal native thymosin beta-4 increased re-epithelialization by 42% at day 4 and 61% at day 7 versus saline, increased wound contraction by ≥11% at day 7, and raised collagen deposition and angiogenesis. As little as 10 pg stimulated keratinocyte migration 2–3-fold in vitro. These results are for native full-length Tbeta4 — not the short TB-500 fragment [1].

**A 2026 systematic review [7]:** TB-500/thymosin beta-4 and BPC-157 are listed among unapproved musculoskeletal peptides with favorable animal-model outcomes but scarce human safety data, potential for serious harm and operation largely outside regulatory oversight.

**WADA status:** Thymosin beta-4 is on the WADA Prohibited List (S2 — peptide hormones and growth factors), banned at all times in and out of competition. The TB-500 fragment implicates this prohibition. Athletes subject to anti-doping rules should treat KLOW as off-limits.

## KLOW vs GLOW — the four-vs-three distinction

KLOW and GLOW are related but distinct research blends. GLOW is a three-peptide blend (GHK-Cu + BPC-157 + TB-500) — it does not contain KPV. KLOW adds the KPV arm (10 mg), making it a four-peptide blend.

The addition of KPV is mechanistically significant: KPV targets NF-kB-driven cytokine transcription in gut epithelium and macrophages via the PepT1 transporter [3]. Community reports often describe KLOW as feeling more anti-inflammatory than GLOW — an anecdotal observation attributed to the KPV arm, not a controlled comparison.

KLOW is also distinct from WOLVERINE (a different research blend). Neither GLOW nor WOLVERINE should be conflated with KLOW.

---

Four channels logged, four literatures cited — a research console that reads the component record and marks the blank rows honestly.